2.1 Study design and participants
This study retrospectively collected post-transplant patients with novel
coronavirus infection who attended Shenzhen No. 3 Hospital from December
2022 to February 2023, and enrolled the general population with novel
coronavirus infection who were hospitalized or treated as outpatients
during the same period, matched by age and gender. The characteristics
of infection and prognosis after novel coronavirus infection were
compared between the renal transplantation population and the general
population.This study was approved and supervised by the ethics
committee of the Third People’s Hospital of Shenzhen (approval number
2023-036-02) and registered in Clinical Trials(NCT05926076).